| The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours R El Ansari, ML Craze, I Miligy, M Diez-Rodriguez, CC Nolan, IO Ellis, ... Breast Cancer Research 20, 1-17, 2018 | 119 | 2018 |
| Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival C Joseph, M Alsaleem, N Orah, PL Narasimha, IM Miligy, S Kurozumi, ... Breast cancer research and treatment 182, 267-282, 2020 | 98 | 2020 |
| Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast MS Toss, I Miligy, A Al-Kawaz, M Alsleem, H Khout, PC Rida, R Aneja, ... Modern Pathology 31 (8), 1226-1236, 2018 | 82 | 2018 |
| Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ I Miligy, P Mohan, A Gaber, MA Aleskandarany, CC Nolan, ... Histopathology 71 (2), 258-268, 2017 | 76 | 2017 |
| Diagnostic concordance and discordance in digital pathology: a systematic review and meta-analysis AS Azam, IM Miligy, PKU Kimani, H Maqbool, K Hewitt, NM Rajpoot, ... Journal of Clinical Pathology 74 (7), 448-455, 2021 | 72 | 2021 |
| Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer A Katayama, IM Miligy, S Shiino, MS Toss, K Eldib, S Kurozumi, CM Quinn, ... Modern Pathology 34 (7), 1271-1281, 2021 | 68 | 2021 |
| Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer C Joseph, M Arshad, S Kurozomi, M Althobiti, IM Miligy, S Al-Izzi, MS Toss, ... Breast Cancer Research and Treatment 174, 387-399, 2019 | 65 | 2019 |
| A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk S Klimov, IM Miligy, A Gertych, Y Jiang, MS Toss, P Rida, IO Ellis, A Green, ... Breast Cancer Research 21, 1-19, 2019 | 54 | 2019 |
| Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma A Laurinavicius, B Plancoulaine, A Rasmusson, J Besusparis, R Augulis, ... Virchows Archiv 468, 493-502, 2016 | 46 | 2016 |
| Semantic annotation for computational pathology: multidisciplinary experience and best practice recommendations N Wahab, IM Miligy, K Dodd, H Sahota, M Toss, W Lu, M Jahanifar, ... The Journal of Pathology: Clinical Research 8 (2), 116-128, 2022 | 42 | 2022 |
| Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS) MS Toss, IM Miligy, KL Gorringe, A AlKawaz, H Khout, IO Ellis, AR Green, ... British journal of cancer 119 (12), 1518-1526, 2018 | 42 | 2018 |
| Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention R Ali, A Al-Kawaz, MS Toss, AR Green, IM Miligy, KA Mesquita, ... Cancer Research 78 (24), 6818-6827, 2018 | 39 | 2018 |
| The prognostic significance of immune microenvironment in breast ductal carcinoma in situ MS Toss, A Abidi, D Lesche, C Joseph, S Mahale, H Saunders, T Kader, ... British journal of cancer 122 (10), 1496-1506, 2020 | 37 | 2020 |
| Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ M Toss, I Miligy, K Gorringe, K Mittal, R Aneja, I Ellis, A Green, E Rakha Journal of Clinical Pathology 73 (2), 76-82, 2020 | 35 | 2020 |
| The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution IM Miligy, MS Toss, KL Gorringe, AHS Lee, IO Ellis, AR Green, EA Rakha British journal of cancer 120 (11), 1075-1082, 2019 | 35 | 2019 |
| PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers R Ali, M Alabdullah, A Alblihy, I Miligy, KA Mesquita, SYT Chan, ... Cancer Letters 469, 124-133, 2020 | 34 | 2020 |
| Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer AI Aljohani, C Joseph, S Kurozumi, OJ Mohammed, IM Miligy, AR Green, ... Breast cancer research and treatment 181, 541-551, 2020 | 33 | 2020 |
| Invasion in breast lesions: the role of the epithelial–stroma barrier EA Rakha, IM Miligy, KL Gorringe, MS Toss, AR Green, SB Fox, ... Histopathology 72 (7), 1075-1083, 2018 | 33 | 2018 |
| Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ IM Miligy, KL Gorringe, MS Toss, AA Al-Kawaz, P Simpson, ... Modern Pathology 31 (12), 1807-1815, 2018 | 30 | 2018 |
| Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: critical review M Toss, I Miligy, AM Thompson, H Khout, AR Green, IO Ellis, EA Rakha The Breast 35, 151-156, 2017 | 30 | 2017 |
